Biofrontera Launches A New, FDA-Approved Red Light Source, The RhodoLED XL Lamp
Portfolio Pulse from Benzinga Newsdesk
Biofrontera Inc. (NASDAQ:BFRI) has launched its FDA-approved RhodoLED XL lamp, designed for use with Ameluz® gel in photodynamic therapy for actinic keratoses. The company began commercial distribution on June 10, 2024.
June 24, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biofrontera Inc. has launched its FDA-approved RhodoLED XL lamp, which is expected to enhance its product portfolio and potentially increase revenue.
The launch of the FDA-approved RhodoLED XL lamp is a significant milestone for Biofrontera, likely to enhance its product offerings and drive revenue growth. The FDA approval adds credibility and market potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100